DANAHER CORP (DAP.DE) Stock Price & Overview
FRA:DAP • US2358511028
Current stock price
The current stock price of DAP.DE is 159.3 EUR. Today DAP.DE is down by -2.31%. In the past month the price decreased by -9.08%. In the past year, price decreased by -16.42%.
DAP.DE Key Statistics
- Market Cap
- 112.647B
- P/E
- 23.57
- Fwd P/E
- 21.65
- EPS (TTM)
- 6.76
- Dividend Yield
- 0.85%
DAP.DE Stock Performance
DAP.DE Stock Chart
DAP.DE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to DAP.DE. When comparing the yearly performance of all stocks, DAP.DE is a bad performer in the overall market: 87.43% of all stocks are doing better.
DAP.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DAP.DE. While DAP.DE has a great health rating, its profitability is only average at the moment.
DAP.DE Earnings
On January 28, 2026 DAP.DE reported an EPS of 2.23 and a revenue of 6.84B. The company beat EPS expectations (2.56% surprise) and missed revenue expectations (-0.52% surprise).
DAP.DE Forecast & Estimates
30 analysts have analysed DAP.DE and the average price target is 225.41 EUR. This implies a price increase of 41.5% is expected in the next year compared to the current price of 159.3.
For the next year, analysts expect an EPS growth of 8.87% and a revenue growth 4.44% for DAP.DE
DAP.DE Groups
Sector & Classification
DAP.DE Financial Highlights
Over the last trailing twelve months DAP.DE reported a non-GAAP Earnings per Share(EPS) of 6.76. The EPS increased by 4.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.71% | ||
| ROA | 4.33% | ||
| ROE | 6.88% | ||
| Debt/Equity | 0.35 |
DAP.DE Ownership
DAP.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| DIM | SARTORIUS STEDIM BIOTECH | 31.35 | 16.259B | ||
| 56S1 | SARTORIUS STEDIM BIOTECH | 31.54 | 16.157B | ||
| SRT3 | SARTORIUS AG-VORZUG | 35.51 | 16.137B | ||
| SRT | SARTORIUS AG | 28.5 | 12.655B | ||
| QIA | QIAGEN N.V. | 15.06 | 7.226B | ||
| 1SXP | SCHOTT PHARMA AG& CO KGAA | 12.38 | 2.033B | ||
| EVT | EVOTEC SE | N/A | 1.555B | ||
| 1EVT | EVOTEC SE | N/A | 1.501B | ||
| GXI | GERRESHEIMER AG | 7.86 | 716.36M | ||
| FF | FINE FOODS & PHARMACEUTICALS | 11.85 | 180.892M | ||
| MLC | MALIN CORP PLC | N/A |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About DAP.DE
Company Profile
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 58,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Company Info
IPO: 1969-12-10
DANAHER CORP
2200 Pennsylvania Ave NW Ste 800W
WASHINGTON WASHINGTON DC US
Employees: 58000
Phone: 18667611444
DANAHER CORP / DAP.DE FAQ
Can you describe the business of DANAHER CORP?
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The company is headquartered in Washington, Washington Dc and currently employs 58,000 full-time employees. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
What is the stock price of DANAHER CORP today?
The current stock price of DAP.DE is 159.3 EUR. The price decreased by -2.31% in the last trading session.
What is the dividend status of DANAHER CORP?
DANAHER CORP (DAP.DE) has a dividend yield of 0.85%. The yearly dividend amount is currently 1.07.
What is the ChartMill rating of DANAHER CORP stock?
DAP.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about DANAHER CORP (DAP.DE) stock?
30 analysts have analysed DAP.DE and the average price target is 225.41 EUR. This implies a price increase of 41.5% is expected in the next year compared to the current price of 159.3.
What is the Price/Earnings (PE) ratio of DANAHER CORP (DAP.DE)?
The PE ratio for DANAHER CORP (DAP.DE) is 23.57. This is based on the reported non-GAAP earnings per share of 6.76 and the current share price of 159.3 EUR.